138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations — M. Polito (2023) | RDL Network
138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations
Johann S. de Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquı́n Mateo, Oliver Sartor, Kim N., Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Goessl, Joe Burgents
Shahneen Sandhu, M. Hussain, J. Mateo, Khawla El Fizazi, F. Saad, N. Shore, K. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, Niven Mehra, C. Goessl, J. Kang, J. Burgents, W. Wu, A. Kohlmann, C. Adelman, J. de Bono
Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, K.N. Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, P. Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Weiwen Wu, Alexander Kohlmann, Carrie A. Adelman, Johann S. de Bono
Anna Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon P. Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin J. Blyth, Declan G. Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phillip K. Darcy, Ygal Haupt, Scott Williams, Elena Castro, David Olmos, David L. Goode, ,
Discussion(0)
No comments yet. Be the first to comment.